

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/830,343	11/23/2001	Karen Akinsanya	033236/0114	6930
75	90 09/29/2004	EXAMINER		
Stephen A Ber	nt	DEBERRY, REGINA M		
Foley & Lardne Washingto Harb		ART UNIT	PAPER NUMBER	
3000 K Street N		1647		
Washington, D	C 20007-5109	DATE MAILED: 09/29/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	ı		Applicatio	n No.	Applicant(s)			
Office Action Summary		09/830,343 AKINSA		AKINSANYA ET A	ANYA ET AL.			
		Examiner		Art Unit				
			Regina M.	DeBerry	1647			
	AILING DATE of this commu	nication appe	ears on the	cover sheet with the	correspondence ad	ldress		
THE MAILING - Extensions of tir after SIX (6) MC - If the period for - If NO period for - Failure to reply v Any reply receiv	ED STATUTORY PERIOD IN COMMUNION IN THIS COMMUNION IN THIS From the mailing date of this compreply specified above is less than thirty (reply is specified above, the maximum swithin the set or extended period for repled by the Office later than three months arm adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136 munication. 30) days, a reply statutory period wi y will, by statute, o	6(a). In no ever within the statut ill apply and will cause the applic	nt, however, may a reply be ti tory minimum of thirty (30) da expire SIX (6) MONTHS from cation to become ABANDONE	mely filed ys will be considered timel n the mailing date of this c ED (35 U.S.C. § 133).	ly. communication.		
Status								
2a) ☐ This ac 3) ☐ Since the	nsive to communication(s) file tion is FINAL . his application is in condition in accordance with the pract	2b)⊠ This a for allowan	action is no	or formal matters, pr		e merits is		
Disposition of C	laims							
4) ⊠ Claim(s) 1-12 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-12 are subject to restriction and/or election requirement.								
Application Pap	ers							
10) The dra Applicar Replace	ecification is objected to by the wing(s) filed on is/are not may not request that any objectment drawing sheet(s) including the or declaration is objected the control of the contr	e: a) acce ection to the d g the correction	epted or b)[drawing(s) be on is require	e held in abeyance. Se d if the drawing(s) is ob	ee 37 CFR 1.85(a). ojected to. See 37 C			
Priority under 35	5 U.S.C. § 119					•		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice of Drafts	rences Cited (PTO-892) sperson's Patent Drawing Review (sclosure Statement(s) (PTO-1449 o ail Date			4) Interview Summan Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	Date	O-152)		

Application/Control Number: 09/830,343

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-12, drawn to the pharmaceutical composition, method of preparing pharmaceutical composition, method of administering composition.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows: species of SEQ ID NO:7.

Applicant is required to elect one species of SEQ ID NO:7. Applicant must elect one amino acid for Xaa1, Xaa2 and Xaa3:

elect one amino acid for Xaa1 (elect either His OR Tyr) and elect one amino acid for Xaa2 (elect either Trp OR Leu) and elect one amino acid for Xaa3 (elect either Tyr OR Arg).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply

Application/Control Number: 09/830,343

Art Unit: 1647

must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner: claims 1, 8 and 11 (SEQ ID NO:7).

The following claim(s) are generic: claims 3, 5, 7, 10, and 12 (SEQ ID NO:6).

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species comprise distinct sequences because they are composed of unrelated or diverse sequences, different coding regions and/or imparts structural and functional differences.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, separate search requirements, and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Regina M. DeBerry whose telephone number is (571) 272-0882. The examiner can normally be reached on 9:00 a.m.-6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda G. Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

AMD RMD 9/17/04 Clyabetr C. Hemmeres

ELIZABETH KEMMERER PRIMARY EXAMINER